{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:10:11Z","timestamp":1783469411828,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.dld.2015.07.155","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T18:18:47Z","timestamp":1439057927000},"page":"978-983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis"],"prefix":"10.1016","volume":"47","author":[{"given":"Sara","family":"Massironi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-3310","authenticated-orcid":false,"given":"Alessandra","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Fanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clorinda","family":"Ciafardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Peracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2015.07.155_bib0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1572-0241.2003.04027.x","article-title":"A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?","volume":"99","author":"Modlin","year":"2004","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0290","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1677\/ERC-10-0152","article-title":"Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters","volume":"17","author":"Niederle","year":"2010","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.dld.2015.07.155_bib0295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000335595","article-title":"Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms","volume":"95","author":"Delle Fave","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2015.07.155_bib0300","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.gtc.2013.01.009","article-title":"Gastric carcinoids (neuroendocrine neoplasms)","volume":"42","author":"Kidd","year":"2013","journal-title":"Gastroenterology Clinics of North America"},{"key":"10.1016\/j.dld.2015.07.155_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"10.1016\/j.dld.2015.07.155_bib0310","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/ajg.2010.341","article-title":"Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971","volume":"105","author":"Ellis","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0315","first-page":"S94","article-title":"Gastric carcinoids","volume":"2","author":"Bordi","year":"1999","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.07.155_bib0320","doi-asserted-by":"crossref","first-page":"287825","DOI":"10.1155\/2012\/287825","article-title":"Current concepts on gastric carcinoid tumors","volume":"2012","author":"Nikou","year":"2012","journal-title":"Gastroenterology Research and Practice"},{"key":"10.1016\/j.dld.2015.07.155_bib0325","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/den.12197","article-title":"Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan","volume":"26","author":"Sato","year":"2014","journal-title":"Digestive Endoscopy"},{"key":"10.1016\/j.dld.2015.07.155_bib0330","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.12698","article-title":"Review article: the investigation and management of gastric neuroendocrine tumours","volume":"39","author":"Basuroy","year":"2014","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2015.07.155_bib0335","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10120-004-0303-6","article-title":"Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis","volume":"8","author":"Hosokawa","year":"2005","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.dld.2015.07.155_bib0340","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.dld.2007.01.018","article-title":"Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours","volume":"39","author":"Ravizza","year":"2007","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2015.07.155_bib0345","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000329043","article-title":"Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate","volume":"95","author":"Merola","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2015.07.155_bib0350","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MEG.0b013e328350fae8","article-title":"Unusually aggressive type 1 gastric carcinoid: a case report with a review of the literature","volume":"24","author":"Spampatti","year":"2012","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.07.155_bib0355","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2169\/internalmedicine.52.0083","article-title":"Multiple gastric G1 neuroendocrine tumors with venous and lymphatic invasion","volume":"52","author":"Tatsuta","year":"2013","journal-title":"Internal Medicine"},{"key":"10.1016\/j.dld.2015.07.155_bib0360","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.3748\/wjg.v19.i46.8687","article-title":"Metastatic type 1 gastric carcinoid: a real threat or just a myth?","volume":"19","author":"Grozinsky-Glasberg","year":"2013","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0365","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.humpath.2011.01.018","article-title":"Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms","volume":"42","author":"La Rosa","year":"2011","journal-title":"Human Pathology"},{"key":"10.1016\/j.dld.2015.07.155_bib0370","first-page":"285","article-title":"Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors","volume":"71","author":"Solcia","year":"1998","journal-title":"Yale Journal of Biology and Medicine"},{"key":"10.1016\/j.dld.2015.07.155_bib0375","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.sla.0000167862.52309.7d","article-title":"Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type","volume":"242","author":"Borch","year":"2005","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.dld.2015.07.155_bib0380","first-page":"93","article-title":"Gastric carcinoids and therapeutic options. Case report and review of the literature","volume":"22","author":"Dobru","year":"2013","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"key":"10.1016\/j.dld.2015.07.155_bib0385","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jss.2010.01.005","article-title":"Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors","volume":"162","author":"Ozao-Choy","year":"2010","journal-title":"Journal of Surgical Research"},{"key":"10.1016\/j.dld.2015.07.155_bib0390","first-page":"379","article-title":"Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia","volume":"57","author":"Hoshino","year":"2010","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0395","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jso.20468","article-title":"Presentation, treatment, and outcome of type 1 gastric carcinoid tumors","volume":"93","author":"Dakin","year":"2006","journal-title":"Journal of Surgical Oncology"},{"key":"10.1016\/j.dld.2015.07.155_bib0400","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0753-3322(02)00282-2","article-title":"Minimally invasive surgery for gastric carcinoid tumor","volume":"56","author":"Otani","year":"2002","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.dld.2015.07.155_bib0405","first-page":"782","article-title":"Fundic endocrine tumors and atrophic gastritis: the value of antrectomy","volume":"26","author":"Guillem","year":"2002","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1016\/j.dld.2015.07.155_bib0410","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/gut.38.5.668","article-title":"Oxyntic endocrine cells of hypergastrinemic patients. Differential response to antrectomy or octreotide","volume":"38","author":"D\u2019Adda","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.dld.2015.07.155_bib0415","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1245\/s10434-009-0687-y","article-title":"Defining surgical indications for type I gastric carcinoid tumor","volume":"16","author":"Gladdy","year":"2009","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/j.dld.2015.07.155_bib0420","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/EJE-08-0420","article-title":"Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours","volume":"159","author":"Grozinsky-Glasberg","year":"2008","journal-title":"European Journal of Endocrinology\/European Federation of Endocrine Societies"},{"key":"10.1016\/j.dld.2015.07.155_bib0425","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1677\/ERC-07-0251","article-title":"Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs","volume":"15","author":"Campana","year":"2008","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.dld.2015.07.155_bib0430","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/00365520410005225","article-title":"Treatment of ECL cell carcinoids with octreotide LAR","volume":"39","author":"Fykse","year":"2004","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0435","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/MEG.0b013e328220eae0","article-title":"Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue","volume":"19","author":"Manfredi","year":"2007","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.07.155_bib0440","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/00365521.2010.539255","article-title":"Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids","volume":"46","author":"Jianu","year":"2011","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0445","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1080\/00365520510023684","article-title":"One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release","volume":"40","author":"Fykse","year":"2005","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0450","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1440-1746.2009.06131.x","article-title":"Treatment of type I gastric neuroendocrine tumors with somatostatin analogs","volume":"25","author":"Khuroo","year":"2010","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.07.155_bib0455","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1530\/EJE-12-0836","article-title":"Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study","volume":"168","author":"Thomas","year":"2013","journal-title":"European Journal of Endocrinology\/European Federation of Endocrine Societies"},{"key":"10.1016\/j.dld.2015.07.155_bib0460","article-title":"Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study","author":"Campana","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.dld.2015.07.155_bib0465","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3748\/wjg.15.2177","article-title":"Gastric carcinoids: between underestimation and overtreatment","volume":"15","author":"Massironi","year":"2009","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0470","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","article-title":"Classification and grading of gastritis. The updated Sydney System. International Workshop on the histopatology of gastritis","volume":"20","author":"Dixon","year":"1994","journal-title":"American Journal of Pathology"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2015.07.155_bib0475","first-page":"S1","article-title":"Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis","volume":"19","author":"Solcia","year":"1995","journal-title":"American Journal of Surgical Pathology"},{"key":"10.1016\/j.dld.2015.07.155_bib0480","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.gastrohep.2009.03.011","article-title":"Treatment of a type I carcinoid gastric tumor through endoscopic mucosal resection using a cap","volume":"32","author":"Muro","year":"2009","journal-title":"Gastroenterologia y Hepatologia"},{"key":"10.1016\/j.dld.2015.07.155_bib0485","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2003-37256","article-title":"Endoscopic mucosal resection in the management of gastric carcinoid tumors","volume":"35","author":"Ichikawa","year":"2003","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2015.07.155_bib0490","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1440-1746.2009.05909.x","article-title":"En-bloc resection of multiple type 1 gastric carcinoids tumors by endoscopic multi-band mucosectomy","volume":"24","author":"Hopper","year":"2009","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.07.155_bib0495","first-page":"212","article-title":"Endoscopic submucosal dissection: experience in an Australian tertiary center","volume":"27","author":"Uygun","year":"2014","journal-title":"Annals of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0500","first-page":"1524","article-title":"Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection","volume":"60","author":"Sato","year":"2013","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0505","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.3748\/wjg.v18.i40.5799","article-title":"Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study","volume":"18","author":"Li","year":"2012","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0510","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2169\/internalmedicine.51.7077","article-title":"Successful endoscopic submucosal dissection of gastric carcinoid in a patient with autoimmune gastritis and systemic lupus erythematosus","volume":"51","author":"Oshima","year":"2012","journal-title":"Internal Medicine"},{"key":"10.1016\/j.dld.2015.07.155_bib0515","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.regpep.2010.01.009","article-title":"The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development","volume":"162","author":"Kidd","year":"2010","journal-title":"Regulatory Peptides"},{"key":"10.1016\/j.dld.2015.07.155_bib0520","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/apt.12090","article-title":"Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A","volume":"36","author":"Fossmark","year":"2012","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2015.07.155_bib0525","doi-asserted-by":"crossref","first-page":"e76462","DOI":"10.1371\/journal.pone.0076462","article-title":"Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis","volume":"8","author":"Moore","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.dld.2015.07.155_bib0530","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jso.23477","article-title":"Long-term results of endoscopic resection for type I gastric neuroendocrine tumors","volume":"109","author":"Uygun","year":"2014","journal-title":"Journal of Surgical Oncology"},{"key":"10.1016\/j.dld.2015.07.155_bib0535","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2015.07.155_bib0540","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/j.1572-0241.1998.00551.x","article-title":"Multimodality treatment for gastric carcinoid tumor with liver metastases","volume":"93","author":"Caplin","year":"1998","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.07.155_bib0545","first-page":"677","article-title":"Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth","volume":"81","author":"Ferraro","year":"1996","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.dld.2015.07.155_bib0550","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1530\/eje.1.01862","article-title":"Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids","volume":"152","author":"Peracchi","year":"2005","journal-title":"European Journal of Endocrinology"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2015.07.155_bib0555","first-page":"S8","article-title":"Hypergastrinemia and gastric enterochromaffin-like cells","volume":"19","author":"Bordi","year":"1995","journal-title":"American Journal of Surgical Pathology"},{"key":"10.1016\/j.dld.2015.07.155_bib0560","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/gast.2002.34231","article-title":"Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas","volume":"123","author":"Peghini","year":"2002","journal-title":"Gastroenterology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865815005617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865815005617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T05:27:05Z","timestamp":1537421225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865815005617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1590865815005617"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2015.07.155","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2015.07.155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}